USFDA approves Pfizer Adcetris combination regimen for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ruchika Sharma13 Feb 2025 2:30 PM ISTNew York: Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License...
USFDA approves label update for Kite's Yescarta CAR T-Cell Therapy to include overall survival data Ruchika Sharma26 Dec 2023 12:00 PM ISTSanta Monica: Kite, a Gilead Company has announced that the U.S. Food and Drug Administration (FDA), has approved a label update for Yescarta...
Roche gets USFDA priority review for Glofitamab to treat relapsed or refractory large B-cell lymphoma Ruchika Sharma7 Jan 2023 2:30 PM ISTGlofitamab is an investigational CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface...
Bristol Myers Squibb bags USFDA nod for CAR T Cell Therapy Breyanzi Ruchika Sharma26 Jun 2022 4:00 PM ISTBreyanzi, a differentiated CAR T cell therapy, is made from a patient's own T cells, which are collected and genetically reengineered to become CAR T...
